Business ❯ Healthcare ❯ Biopharmaceuticals

Drug Development

Clinical Trials Precision Medicine Antibody Therapy Immunology Rare Diseases AI-Accelerated Drug Development Liquidia Corporation Clinical-stage Companies

Parabilis Prices Upsized IPO at $20, Raising $670 Million

Proceeds will fund clinical trials of Parabilis’s Helicons peptide platform.

Simulations Plus Beats Q2, Lowers FY2026 Profit Outlook

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

MPM BioImpact Exits MBX, MoonLake, Crinetics in Q3, SEC Filing Shows

Liquidia Reports 900+ Yutrepia Prescriptions in 11 Weeks, Targets Profitability Within 3–4 Quarters